Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Luca Laurenti, Francesca R. Mauro, Stefano Molica, Agostino Cortelezzi, Angelo M. Carella, Francesco Zaja, Annalisa Chiarenza, Francesco Angrilli, Francesco Nobile, Roberto Marasca, Caterina Musolino, Maura Brugiatelli, Alfonso Piciocchi, Marco Vignetti, Paola Fazi, Giuseppe Gentile, Maria S. De Propris, Irene Della Starza, Marilisa Marinelli, Sabina ChiarettiIlaria Del Giudice, Mauro Nanni, Francesco Albano, Antonio Cuneo, Anna Guarini, Robin Foà

Risultato della ricerca: Contributo in rivistaArticolo in rivista

7 Citazioni (Scopus)

Abstract

In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.
Lingua originaleEnglish
pagine (da-a)198-203
Numero di pagine6
RivistaLeukemia Research
Volume38
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • Alemtuzumab
  • Biology
  • CLL
  • Chronic lymphocytic leukemia
  • Fludarabine
  • Young

Fingerprint Entra nei temi di ricerca di 'Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile'. Insieme formano una fingerprint unica.

Cita questo